Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Completed · Phase 2
Conditions studied: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
In brief
Phase II trial to study the effectiveness of bortezomib in treating patients who have relapsed or refractory Hodgkin's lymphoma. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth.
Key facts
- Study ID
- NCT00082966
- Run by
- National Cancer Institute (NCI)
- People needed
- 43
- Starts
- 2004-03-01
- Last updated by the study team
- 2015-12-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed classical Hodgkin's lymphoma
- No bone marrow biopsies or fine needle aspirates as the sole means of diagnosis
- Core biopsies allowed if they contain adequate tissue for primary diagnosis
- The following subtypes are allowed:
- Nodular sclerosis
- Lymphocyte rich
- Mixed cellularity
- Lymphocyte depletion
- Classical Hodgkin's lymphoma, not otherwise specified
- No nodular lymphocyte-predominant Hodgkin's lymphoma
- Relapsed or refractory disease after at least 1 prior standard systemic cytotoxic chemotherapy regimen
- Measurable disease by physical exam or imaging studies
- Any tumor mass > 1 cm is allowed
- No non-measurable disease only, including the following:
- Bone lesions
- Ascites
- Pleural or pericardial effusion
- Lymphangitis cutis/pulmonis
- Bone marrow
- No curative option available with high-dose therapy and stem cell transplantation
- Performance status - 0-2
- Absolute neutrophil count ≥ 750/mm\^3
- Platelet count ≥ 75,000/mm\^3
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST ≤ 2.5 times ULN
Where it is running
- Cancer and Leukemia Group B — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.